Home > Publications database > Onconephrology: The Significance of Renal Function for the Development, Diagnosis, and Treatment of Cancer. > print

001     298902
005     20250216015234.0
024 7 _ |a 10.3238/arztebl.m2024.0193
|2 doi
024 7 _ |a pmid:39417369
|2 pmid
024 7 _ |a altmetric:171242528
|2 altmetric
037 _ _ |a DKFZ-2025-00341
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Delecluse, Susanne
|0 P:(DE-He78)3877ae274d0271d6bf311bb46539f013
|b 0
|e First author
|u dkfz
245 _ _ |a Onconephrology: The Significance of Renal Function for the Development, Diagnosis, and Treatment of Cancer.
260 _ _ |a Köln
|c 2024
|b Dt. Ärzte-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1739453839_2238
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D400# / https://di.aerzteblatt.de/int/archive/article/241946
520 _ _ |a Modern treatment strategies have markedly improved the chances of survival for patients with cancer. As the population ages, cancer is becoming more common, as is chronic kidney disease (CKD). CKD increases the risk of cancer; conversely, cancer treatments can cause CKD.This review is based on publications retrieved by a selective literature search concerning the epidemiology and comorbidities of cancer and kidney diseases, the renal side effects of new anticancer drugs, and the need to consider renal function in cancer treatment.The prevalence of severe CKD in Germany is 2.3%. Persons who have CKD, are on dialysis, or have undergone kidney transplantation are 1.2 to 3.5 times more likely to develop cancer than the general population. For patients who have CKD or are dialysis-dependent, the doses of approximately 67% of anticancer drugs need to be adjusted on the basis of their glomerular filtration rate and the renally excreted fraction of the drug. The optimal efficacy of therapeutic drugs, as well as of those used for diagnostic purposes, and the minimization of side effects, depend critically on adapted dosing and on proper timing of administration before or after dialysis. Modern anticancer drugs can also cause acute kidney damage (incidence with checkpoint inhibitors: 2-16%).Patients who have CKD, are on dialysis, or have undergone kidney transplantation make up a considerable fraction of persons being treated for cancer, and they need interdisciplinary treatment.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neoplasms: complications
|2 MeSH
650 _ 2 |a Neoplasms: therapy
|2 MeSH
650 _ 2 |a Renal Insufficiency, Chronic: therapy
|2 MeSH
650 _ 2 |a Renal Insufficiency, Chronic: complications
|2 MeSH
650 _ 2 |a Renal Insufficiency, Chronic: diagnosis
|2 MeSH
650 _ 2 |a Renal Insufficiency, Chronic: physiopathology
|2 MeSH
650 _ 2 |a Antineoplastic Agents: adverse effects
|2 MeSH
650 _ 2 |a Germany: epidemiology
|2 MeSH
650 _ 2 |a Glomerular Filtration Rate
|2 MeSH
650 _ 2 |a Kidney Transplantation
|2 MeSH
650 _ 2 |a Renal Dialysis
|2 MeSH
650 _ 2 |a Prevalence
|2 MeSH
700 1 _ |a Harder, Fridtjof
|b 1
700 1 _ |a Keller, Frieder
|b 2
700 1 _ |a Zeier, Martin
|b 3
700 1 _ |a Zschäbitz, Stefanie
|b 4
773 _ _ |a 10.3238/arztebl.m2024.0193
|g Vol. 121, no. 24
|0 PERI:(DE-600)2406159-1
|n 24
|p 793-799
|t Deutsches Ärzteblatt international
|v 121
|y 2024
|x 1866-0452
909 C O |o oai:inrepo02.dkfz.de:298902
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)3877ae274d0271d6bf311bb46539f013
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b DTSCH ARZTEBL INT : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b DTSCH ARZTEBL INT : 2022
|d 2025-01-07
920 1 _ |0 I:(DE-He78)D400-20160331
|k D400
|l Pathologie infektionsbedingter Tumoren
|x 0
920 0 _ |0 I:(DE-He78)D400-20160331
|k D400
|l Pathologie infektionsbedingter Tumoren
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D400-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21